Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 127

Sort by

Sort Order Select

Journal Articles

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

Blood (2019) 133 (26): 2765–2775.

https://doi.org/10.1182/blood-2019-01-896290

Published: 2019

Includes: Supplemental data

Journal Articles

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Susan O’Brien, Richard R. Furman, Steven Coutre, Ian W. Flinn, Jan A. Burger, Kristie Blum, Jeff Sharman, William Wierda, Jeffrey Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Ying Luan, Danelle F. James, Alvina D. Chu, John C. Byrd

Blood (2018) 131 (17): 1910–1919.

https://doi.org/10.1182/blood-2017-10-810044

Published: 2018

Includes: Supplemental data

Journal Articles

Long-Term Outcome of CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors in the Second Line: A Single Center Experience

Kamal Chamoun, MD, Hagop M. Kantarjian, MD, Mary Abisola Akosile, PhD, Rita Assi, MD, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Tapan Kadia, MD, Marina Konopleva, MD PhD, Zeev Estrov, MD, Courtney D. DiNardo, MDMSc, Naval Daver, MD, Naveen Pemmaraju, MD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, William Wierda, MD, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 1594.

https://doi.org/10.1182/blood.V130.Suppl_1.1594.1594

Published: 2017

Journal Articles

Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatment

Ghayas C. Issa, Hagop M. Kantarjian, Graciela Nogueras Gonzalez, Gautam Borthakur, Guilin Tang, William Wierda, Koji Sasaki, Nicholas J. Short, Farhad Ravandi, Tapan Kadia, Keyur Patel, Raja Luthra, Alessandra Ferrajoli, Guillermo Garcia-Manero, Mary Beth Rios, Sara Dellasala, Elias Jabbour, Jorge E. Cortes

Blood (2017) 130 (19): 2084–2091.

https://doi.org/10.1182/blood-2017-07-792143

Published: 2017

Includes: Supplemental data

Journal Articles

Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab

Blood (2017) 129 (10): 1275–1283.

https://doi.org/10.1182/blood-2016-09-736686

Published: 2017

Journal Articles

Acalabrutinib Monotherapy in Patients with Richter Transformation from the Phase 1/2 ACE-CL-001 Clinical Study

Peter Hillmen, Anna Schuh, MD PhD, Toby A. Eyre, MD, John M. Pagel, MD PhD, Jennifer R. Brown, MD PhD, Paolo Ghia, John N. Allan, MD, William Wierda, MDPhD, Ahmed Hamdy, MBBCh, Jane Huang, MD, Raquel Izumi, PhD, Priti Patel, Min Hui Wang, John C. Byrd, MD

Blood (2016) 128 (22): 60.

https://doi.org/10.1182/blood.V128.22.60.60

Published: 2016

Journal Articles

Solid Tumors in Patients with Chronic Lymphocytic Leukemia Who Received Frontline Lenalidomide Therapy: Distribution and Clinical Outcomes

Ahmad Alhuraiji, MD MRCP, Lorenzo Falchi, MD, Michael Keating, MBBS, Zeev Estrov, MD, Paolo Strati, MD, William Wierda, MD PhD, Nitin Jain, MD, Philip A Thompson, MBBS, Alessandra Ferrajoli, MD

Blood (2016) 128 (22): 5573.

https://doi.org/10.1182/blood.V128.22.5573.5573

Published: 2016

Journal Articles

Front-Line Treatment with Ofatumumab for Older Unfit Patients with Chronic Lymphocytic Leukemia

Candida Vitale, MD, Maria Ciccone, MD, Christina Hinojosa, Michael Keating, MBBS, Naveen Pemmaraju, MD, Susan O'Brien, MD, William Wierda, MD PhD, Deborah A Thomas, MD, Gautam Borthakur, MD, Maro Ohanian, DO, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD

Blood (2015) 126 (23): 5292.

https://doi.org/10.1182/blood.V126.23.5292.5292

Published: 2015

Journal Articles

RAS/RAF Pathway Mutations Define a Distinct Subset of Chronic Lymphocytic Leukemia

Rashmi Kanagal-Shamanna, MD, Raja Luthra, PhD, Madan Luthra, PhD, Xinyan Lu, MD, Mark Routbort, MD PhD, Nitin Jain, MD, Michael Keating, MBBS, L Jeffrey Medeiros, MD, William Wierda, MD PhD, Keyur P. Patel, MD PhD

Blood (2015) 126 (23): 1730.

https://doi.org/10.1182/blood.V126.23.1730.1730

Published: 2015

Journal Articles

Outcome of Patients with T-Cell ALL Post Frontline Therapy Failure

Christine Parseghian, MD, Hagop M Kantarjian, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, William Wierda, MD PhD, Tapan Kadia, MD, Srdan Verstovsek, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Koichi Takahashi, MD, Nitin Jain, MD, Sherry Pierce, BSN, BA, Elias Jabbour, MD

Blood (2015) 126 (23): 4873.

https://doi.org/10.1182/blood.V126.23.4873.4873

Published: 2015

Journal Articles

Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)

Maro Ohanian, DO, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Michael Andreeff, MD PhD, Elias Jabbour, Marina Konopleva, MD PhD, Miranda Lim, BSN, Sherry Pierce, BSN, BA, Susan O'Brien, MD, Bradley G. Somer, MD, Ana Tari, PhD, William Wierda, MD PhD, Srdan Verstovsek, MD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 3801.

https://doi.org/10.1182/blood.V126.23.3801.3801

Published: 2015

Journal Articles

Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin

Blood (2015) 126 (23): 3776.

https://doi.org/10.1182/blood.V126.23.3776.3776

Published: 2015

Journal Articles

Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia

Tapan Kadia, MD, Farhad Ravandi, MD, Naval Daver, MD, Gautam Borthakur, MD, Jorge E. Cortes, MD, Elias Jabbour, Steven M. Kornblau, MD, Srdan Verstovsek, MD, William Wierda, MD PhD, Jan A Burger, MD PhD, Zeev Estrov, MD, Courtney DiNardo, MD, Xiao Qin Dong, Naveen Pemmaraju, MD, Maro Ohanian, DO, Koichi Takahashi, MD, Stephany Hendrickson, RN, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 4779.

https://doi.org/10.1182/blood.V126.23.4779.4779

Published: 2015

Journal Articles

Frontline Hyper-CVAD with Ponatinib for Patients (pts) with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Results of a Phase II Study

Koji Sasaki, MD, Susan O'Brien, MD, Farhad Ravandi, MD, Deborah A Thomas, MD, Haim G Moore, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Musa Yilmaz, MD, Tapan Kadia, MD, Rebecca Garris, Guillermo Garcia-Manero, MD, Twilla Victoria Jeanis, RN, Jad Chahoud, MD, Gautam Borthakur, MD, William Wierda, MD PhD, Alessandra Ferrajoli, MD, Hagop M. Kantarjian, MD, Elias Jabbour

Blood (2015) 126 (23): 2496.

https://doi.org/10.1182/blood.V126.23.2496.2496

Published: 2015

Journal Articles

Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML)

Blood (2015) 126 (23): 2541.

https://doi.org/10.1182/blood.V126.23.2541.2541

Published: 2015

Journal Articles

Identification of B Cell Receptor Antigens in the Chronic Lymphocytic Leukemia Microenvironment

Elisa ten Hacken, PhD, Thomas Oellerich, MD, Maria Gounari, PhD, Julia Hoellenriegel, MS, Kuan-Ting Pan, PhD, Susan O'Brien, MD, William Wierda, MD PhD, Alessandra Ferrajoli, MD, Zeev Estrov, MD, Michael J. Keating, MD, Henning Urlaub, PhD, Paolo Ghia, MD PhD, Jan A. Burger, MD PhD

Blood (2015) 126 (23): 2922.

https://doi.org/10.1182/blood.V126.23.2922.2922

Published: 2015

Journal Articles

Cord Blood Derived Natural Killer Cells Engineered with a Chimeric Antigen Receptor Targeting CD19 and Expressing IL-15 Have Long Term Persistence and Exert Potent Anti-Leukemia Activity

Enli Liu, MD MS, Yijiu Tong, Gianpietro Dotti, MD, Barbara Savoldo, MD, Muharrem Muftuoglu, Kayo Kondo, PhD, Malini Mukherjee, Jordan S. Orange, MD PhD, Catherine Sobieski, Abdullah Alsuliman, Hila Shaim, MD, Nobuhiko Imahashi, MD PhD, Michael J. Keating, MD, Chitra M. Hosing, MD, Nina Shah, MD, William Wierda, MD PhD, Richard Champlin, MD, Elizabeth J. Shpall, MD, Katayoun Rezvani, MDPhD

Blood (2015) 126 (23): 3091.

https://doi.org/10.1182/blood.V126.23.3091.3091

Published: 2015

Journal Articles

Stimulation of the B-Cell Receptor (BCR) Induces Successive Activation of STAT3 and Nuclear Factor-Kappa-B in CLL Cells

Uri Rozovski, MD, David M. Harris, Ping LI, PhD, Zhiming Liu, Alessandra Ferrajoli, MD, Jan A Burger, MD PhD, Philip Thompson, MBBS, Nitin Jain, MD, William Wierda, MD PhD, Michael Keating, MBBS, Zeev Estrov, MD

Blood (2015) 126 (23): 4125.

https://doi.org/10.1182/blood.V126.23.4125.4125

Published: 2015

Journal Articles

IKZF3 p.L162R Is a Recurrent Hotspot Mutation in Chronic Lymphocytic Leukemia (CLL)

Koichi Takahashi, MD, Candida Vitale, MD, Carlos Bueso-Ramos, Feng Wang, PhD, Ekaterina Kim, MS, Jianhua Zhang, Curtis Gumbs, Mark Routbort, MD PhD, Zeev Estrov, MD, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Michael Keating, MBBS, Andrew Futreal, PhD, William Wierda, MD PhD

Blood (2015) 126 (23): 4136.

https://doi.org/10.1182/blood.V126.23.4136.4136

Published: 2015

Journal Articles

P300 Acetylates STAT3 and Increases Its Constitutive Transcriptional Activity in CLL Cells

Blood (2015) 126 (23): 4143.

https://doi.org/10.1182/blood.V126.23.4143.4143

Published: 2015

NARROW

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Long-Term Outcome of CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors in the Second Line: A Single Center Experience

Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatment

Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab

Acalabrutinib Monotherapy in Patients with Richter Transformation from the Phase 1/2 ACE-CL-001 Clinical Study

Solid Tumors in Patients with Chronic Lymphocytic Leukemia Who Received Frontline Lenalidomide Therapy: Distribution and Clinical Outcomes

Front-Line Treatment with Ofatumumab for Older Unfit Patients with Chronic Lymphocytic Leukemia

RAS/RAF Pathway Mutations Define a Distinct Subset of Chronic Lymphocytic Leukemia

Outcome of Patients with T-Cell ALL Post Frontline Therapy Failure

Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin

Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia

Frontline Hyper-CVAD with Ponatinib for Patients (pts) with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Results of a Phase II Study

Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML)

Identification of B Cell Receptor Antigens in the Chronic Lymphocytic Leukemia Microenvironment

Cord Blood Derived Natural Killer Cells Engineered with a Chimeric Antigen Receptor Targeting CD19 and Expressing IL-15 Have Long Term Persistence and Exert Potent Anti-Leukemia Activity

Stimulation of the B-Cell Receptor (BCR) Induces Successive Activation of STAT3 and Nuclear Factor-Kappa-B in CLL Cells

IKZF3 p.L162R Is a Recurrent Hotspot Mutation in Chronic Lymphocytic Leukemia (CLL)

P300 Acetylates STAT3 and Increases Its Constitutive Transcriptional Activity in CLL Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only